Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 6,453 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward Md Kaye sold 6,453 shares of the business’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $30.87, for a total transaction of $199,204.11. Following the transaction, the director directly owned 71,102 shares in the company, valued at approximately $2,194,918.74. The trade was a 8.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Stoke Therapeutics Trading Down 0.6%

STOK stock traded down $0.18 during trading on Friday, reaching $30.87. The stock had a trading volume of 602,753 shares, compared to its average volume of 917,923. The firm has a fifty day moving average price of $28.90 and a 200 day moving average price of $19.69. The company has a market capitalization of $1.76 billion, a P/E ratio of 46.07 and a beta of 1.14. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The business had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. Sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on STOK. Needham & Company LLC lifted their price objective on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Wedbush lifted their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. increased their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Monday, November 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Stoke Therapeutics in a report on Monday. Finally, BTIG Research restated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Buy” and an average price target of $31.00.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of STOK. Generali Investments Management Co LLC bought a new position in shares of Stoke Therapeutics during the third quarter valued at approximately $41,000. BNP Paribas Financial Markets boosted its position in Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares during the period. Tower Research Capital LLC TRC grew its stake in Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the last quarter. AlphaQuest LLC acquired a new stake in Stoke Therapeutics in the first quarter worth $72,000. Finally, US Bancorp DE lifted its stake in Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after buying an additional 11,108 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.